192 related articles for article (PubMed ID: 15105449)
1. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary?
Foster MC; Helvie MA; Gregory NE; Rebner M; Nees AV; Paramagul C
Radiology; 2004 Jun; 231(3):813-9. PubMed ID: 15105449
[TBL] [Abstract][Full Text] [Related]
2. Atypia Involving Fibroadenomas: Outcomes and Upgrade Rates.
Aripoli A; Winblad O; Balanoff C; Peterson J; Smith C; Huppe A; Hill M; Wermuth D; Gloyeske N
J Breast Imaging; 2024 May; 6(3):254-260. PubMed ID: 38554256
[TBL] [Abstract][Full Text] [Related]
3. Upgrade Rates of Variant Lobular Carcinoma In Situ Compared to Classic Lobular Carcinoma In Situ Diagnosed in Core Needle Biopsies: A 10-Year Single Institution Retrospective Study.
Harinath L; Villatoro TM; Clark BZ; Fine JL; Yu J; Carter GJ; Diego E; McAuliffe PF; Mai P; Lu A; Zuley M; Berg WA; Bhargava R
Mod Pathol; 2024 Apr; 37(4):100462. PubMed ID: 38428736
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of screening mammography in women with a history of lobular carcinoma in situ or atypical hyperplasia of the breast.
Houssami N; Abraham LA; Onega T; Collins LC; Sprague BL; Hill DA; Miglioretti DL
Breast Cancer Res Treat; 2014 Jun; 145(3):765-73. PubMed ID: 24800915
[TBL] [Abstract][Full Text] [Related]
5. Surgical outcomes of borderline breast lesions detected by needle biopsy in a breast screening program.
Flegg KM; Flaherty JJ; Bicknell AM; Jain S
World J Surg Oncol; 2010 Sep; 8():78. PubMed ID: 20822548
[TBL] [Abstract][Full Text] [Related]
6. UK national survey of management of breast lobular carcinoma in situ.
Chester R; Bokinni O; Ahmed I; Kasem A
Ann R Coll Surg Engl; 2015 Nov; 97(8):574-7. PubMed ID: 26492902
[TBL] [Abstract][Full Text] [Related]
7. Upgrade of high-risk breast lesions detected on mammography in the Breast Cancer Surveillance Consortium.
Menes TS; Rosenberg R; Balch S; Jaffer S; Kerlikowske K; Miglioretti DL
Am J Surg; 2014 Jan; 207(1):24-31. PubMed ID: 24112677
[TBL] [Abstract][Full Text] [Related]
8. The lobular neoplasia enigma: management and prognosis in a long follow-up case series.
Metovic J; Abate SO; Borella F; Vissio E; Bertero L; Mariscotti G; Durando M; Senetta R; Ala A; Benedetto C; Sapino A; Cassoni P; Castellano I
World J Surg Oncol; 2021 Mar; 19(1):80. PubMed ID: 33736652
[TBL] [Abstract][Full Text] [Related]
9. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.
Hartmann LC; Radisky DC; Frost MH; Santen RJ; Vierkant RA; Benetti LL; Tarabishy Y; Ghosh K; Visscher DW; Degnim AC
Cancer Prev Res (Phila); 2014 Feb; 7(2):211-7. PubMed ID: 24480577
[TBL] [Abstract][Full Text] [Related]
10. Upgrade Rates and Breast Cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions.
Laws A; Leonard S; Hershey E; Stokes S; Vincuilla J; Sharma E; Milliron K; Garber JE; Merajver SD; King TA; Pilewskie ML
Ann Surg Oncol; 2024 May; 31(5):3120-3127. PubMed ID: 38261128
[TBL] [Abstract][Full Text] [Related]
11. Determination of Factors Associated with Upstage in Atypical Ductal Hyperplasia to Identify Low-Risk Patients Where Active Surveillance May be an Alternative.
Greene AJE; Davis J; Moon J; Dubin I; Cruz A; Gupta M; Moazzez A; Ozao-Choy J; Gupta E; Manchandia T; Kalantari BN; Rahbar G; Dauphine C
Ann Surg Oncol; 2024 May; 31(5):3177-3185. PubMed ID: 38386195
[TBL] [Abstract][Full Text] [Related]
12. Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
Huang CY; Chang RF; Lin CY; Hsieh MS; Liao PC; Wang YJ; Kao YC; Porta L; Lin PY; Lee CC; Lee YH
Histopathology; 2024 May; 84(6):983-1002. PubMed ID: 38288642
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of atypical lobular hyperplasia managed by active surveillance or immediate surgery.
Han LK; Lee J; Dodelzon K; Towne WS; Zhou XK; Ginter PS; Marti JL
World J Surg; 2024 May; 48(5):1149-1156. PubMed ID: 38558414
[TBL] [Abstract][Full Text] [Related]
14. An update on the management of breast atypical ductal hyperplasia.
Schiaffino S; Cozzi A; Sardanelli F
Br J Radiol; 2020 Jun; 93(1110):20200117. PubMed ID: 32207989
[TBL] [Abstract][Full Text] [Related]
15. AI analytics can be used as imaging biomarkers for predicting invasive upgrade of ductal carcinoma in situ.
Yoon J; Yang J; Lee HS; Kim MJ; Park VY; Rho M; Yoon JH
Insights Imaging; 2024 Apr; 15(1):100. PubMed ID: 38578585
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of atypical (B3) core biopsy lesions diagnosed across BreastScreen NSW, Australia.
Chou R; Tran D; Descallar J; Jalaludin B; Soon PS
Breast; 2024 Jun; 75():103720. PubMed ID: 38564975
[TBL] [Abstract][Full Text] [Related]
17. Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants.
Chung HL; Middleton LP; Sun J; Whitman GJ
Breast Cancer Res Treat; 2024 Jun; 205(3):545-554. PubMed ID: 38472593
[TBL] [Abstract][Full Text] [Related]
18. Management of Breast Intraductal Papilloma Diagnosed on Core Needle Biopsy: Excision or Follow-up?
Gillani M; Idress R; Afzal S; Khan M; Shahzad H; Sattar AK
Cureus; 2024 Feb; 16(2):e54716. PubMed ID: 38523979
[TBL] [Abstract][Full Text] [Related]
19. B3 Breast Lesions: Positive Predictive Value and Follow-Up on a Large Single-Institution Series.
Bernini M; Spolveri F; Tofani L; De Benedetto D; Bicchierai G; Bellini C; Morrone D; Nori Cucchiari J; Bianchi S; Livi L; Orzalesi L; Meattini I
J Surg Res; 2024 May; 299():366-373. PubMed ID: 38815523
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
